# US 9,518,995 B2 · FKBP52-Tau interaction as a novel therapeutical target for treating the neurological disorders involving Tau dysfunction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,518,995 B2
- Document ID: US9518995B2
- Status: Granted
- Kind: B2
- Application number: 14/814,674
- Filed: 2015-07-31
- Published: 2016-02-18
- Granted: 2016-12-13
- Earliest claimed: 2009-09-24
- Assignees: Institut National De La Sante Et De La Recherche Medicale (Inserm)
- Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM)
- Inventors: Etienne Baulieu; Beatrice Chambraud
- Web page: https://patentgrep.com/patent/US9518995B2

## CPC

- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2333/4709: Amyloid plaque core protein
- G01N 2333/99: Isomerases (5.)
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N 2800/28: Neurological disorders
- G01N 2800/2821: Alzheimer
- G01N 2800/2828: Prion diseases
- G01N 2800/2835: Movement disorders, e.g. Parkinson, Huntington, Tourette
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Candidate compounds for use in neuro-protection and repair in neurological disorders involving Tau dysfunction (including Alzheimer's disease) are identified from a direct interaction between proteins FKBP52 and Tau. The method for screening a drug for the prevention and treatment of neurological disorders involving Tau dysfunction includes determining the ability of a candidate compound, to modulate binding between a Tau polypeptide and a FKBP52 polypeptide, and selecting positively the candidate compound that modulates binding.

## Claims

### Claim 1

A method of diagnosing and treating a subject thought to have or be predisposed to having a neurological disorder involving Tau dysfunction, which comprises the steps of
I) obtaining a sample of interest from said subject,
II) measuring a concentration of the FKBP52 protein in the sample by using an antibody, an antibody derivative or an antibody fragment which binds specifically to the FKBP52 protein, and
III) administering an effective amount of a compound which modulates a FKBP52 protein level in subjects having or being predisposed to having a neurological disorder involving Tau dysfunction so as to increase the FKBP52 protein level in the subjects.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neurological disorder involving Tau dysfunction is Alzheimer's disease.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the sample of interest is selected from the group consisting of a cell sample, a biological fluid sample and a biopsy sample obtained from a subject's tissue.

### Claim 4 (depends on 3)

The method of claim 3, wherein the biological fluid sample is selected from the group consisting of blood, serum, urine and spinal fluid.

### Claim 5 (depends on 3)

The method of claim 3, wherein the cell sample comprises pre frontal cortex cells.